Łukasz Żukowski

Background/Objectives: Recent advancements in medical imaging have provided tools that significantly enhance diagnostic precision and patient care. Among these, NP-59 SPECT/CT imaging has emerged as a promising method for assessing adrenal gland functionality. Current gaps in clinical practice, including the lack of specific diagnostic biomarkers and the paucity of clinical trials demonstrating the efficacy of adrenalectomy in alleviating comorbidities, necessitate the search for other diagnostic methods. Management becomes more challenging when bilateral adrenal adenomas are present. Demonstrating lateralization in cortisol secretion may greatly assist in treatment selection. Unilateral secretion of cortisol indicates autonomy and therefore adrenalectomy should be preferred. The aim of this study was to evaluate the usefulness of NP-59 SPECT/CT in the management of MACS. Methods: We investigated 20 patients with benign bilateral adrenal incidentalomas and MACS between the years 2023 and 2025. The first group (70%) consisted of patients with only hypertension, without additional comorbidities (hypertension only, HO). The second group (30%) consisted of hypertensive patients with additional comorbidities (hypertension with comorbidities, HC). Visualizations of adrenal glands metabolic activity were conducted using the SPECT/CT system after intravenous injection of NP-59. Abdominal SPECT/CT was performed at 3, 5, and 7 days after tracer injection. Lateralization was established when only single adrenal uptake occurred as early as the third day. Results: Six (30%) patients demonstrated lateralization during NP-59 SPECT scintigraphy. All these patients belonged to the HO group and accounted for 43% of it. Conclusions: NP-59 SPECT scintigraphy is valuable in the identification of unilateral cortisol secretion and guiding treatment decisions such as adrenalectomy versus conservative management. Prospective studies are needed to determine its clinical utility.

Radioactive iodine therapy requires individualized decisions regarding patient selection, administered activity planning, imaging assessment, and follow-up. This systematic review summarizes current applications of artificial intelligence (AI) in the ¹³¹ I treatment pathway and evaluates barriers limiting clinical implementation. Following PRISMA 2020 guidelines, PubMed, Scopus, Web of Science, and Wiley databases were searched for original studies involving human patients treated with ¹³¹ I for differentiated thyroid cancer or benign thyroid disease, where AI, deep learning (DL), or machine learning (ML) methods were utilized. Evidence was synthesized, and study quality was assessed using the NIH/NHLBI Study Quality Assessment Tool. Among 775 identified records, 24 studies met inclusion criteria. AI applications included pretreatment decision support, detection and characterization of iodine-avid disease, dosimetry and activity optimization, radiation-safety assessment, treatment response prediction, levothyroxine dose estimation, and recurrence-risk stratification. The available evidence was dominated by retrospective, single-center studies, primarily focused on differentiated thyroid cancer, with limited external validation. AI has the potential to improve standardization and personalization of ¹³¹ I therapy, but heterogeneous methodologies and insufficient evidence of clinical utility currently restrict routine adoption. Prospective multicenter studies with harmonized endpoints and robust validation are required to facilitate clinical translation.

The purpose of this study was to assess the clinical usefulness of assaying the fibroblast growth factor (FGF-23), Klotho, osteocalcin, N-terminal telopeptide of type I collagen (NTX), and sclerostin levels in patients with primary hyperparathyroidism (PHPT) as markers of bone damage as well as for surgical treatment success. Seventeen patients with hypercalcemic PHPT and normal kidney function were studied. In all patients, PTH (parathormone), serum calcium, and creatinine were performed before and six months after parathyroidectomy (PTX). The studied group included patients whose PTH and calcium concentrations normalized post-operatively and with confirmed histopathological diagnosis. The control group consisted of nine age-matched healthy volunteers. The PHPT patients had elevated concentrations of FGF-23, osteocalcin, and NTX and reduced levels of sclerostin, as compared to the control group. After PTX, osteocalcin, NTX, and sclerostin levels normalized. The plasma values of FGF-23 decreased significantly, but remained higher than in healthy subjects. Serum Klotho protein levels did not differ significantly in the two groups. These results suggest that osteocalcin and NTX may potentially be considered as markers of PHPT progression. Additionally, serum normalization of osteocalcin, NTX, and sclerostin might be considered as indicators of PTX success. On the other hand, FGF-23 can represent a parameter reflecting the degree of calcium–phosphate imbalance in PHPT patients, but its usefulness in monitoring the effects of PTX requires further research. The clinical utility of assaying Klotho in PHPT remains to be confirmed.

Background: The paper presents a pre-processing method which, based on positron-emission tomography (PET) images of ¹⁸F-fluorodeoxyglucose ([18F] FDG) hypermetabolic pulmonary nodules, makes it possible to obtain additional visual characteristics and use them to enhance the specificity of imaging. Material and Methods: A retrospective analysis of 69 FDG-PET/CT scans of solitary hypermetabolic pulmonary nodules (40 cases of lung cancer and 29 benign tumours), where in each case, the standardised uptake value of the hottest voxel within the defined volume of interest was greater than 2.5 (SUVmax > 2.5). No diagnosis could be made based on these SUVmax values. All of the PET DICOM images were transformed by means of the pre-processing method for contouring the uptake levels of [18F] FDG (PCUL-FDG). Next, a multidimensional comparative analysis was conducted using a synthetic variable obtained by calculating the similarities based on the generalised distance measure for non-metric scaling (GDM2) from the pattern object. The calculations were performed with the use of the R language. Results: The PCUL-FDG method revealed 73.9% hypermetabolic nodules definitively diagnosed as either benign or malignant lesions. As for the other 26.1% of the nodules, there was uncertainty regarding their classification (some had features suggesting malignancy, while the characteristics of others made it impossible to confirm malignancy with a high degree of certainty). Conclusions: Application of the PCUL-FDG method enhances the specificity of PET in imaging solitary hypermetabolic pulmonary nodules. Images obtained using the PCUL-FDG method can serve as point of departure for automatic analysis of PET data based on convolutional neural networks.

Background: nowadays, primary aldosteronism (PA) is suggested to be the most frequent cause of secondary hypertension and it reaches 10% of whole hypertensive population. The CYP11B2 promoter polymorphism might cause aldosterone overproduction. The aim of this study was to establish whether the polymorphism CYP11B2 promoter has a significant impact on diagnostic of PA. Material and Methods: study group consisted of 239 hypertensive patients previously diagnosed with adrenal incidentaloma. For diagnose of PA were performed: screening test–aldosterone-renin ratio (ARR) and saline suppression test (SIT) as a confirmatory test. Genotyping was carried out by the real time PCR method. The significance of differences between the groups was evaluated through Student’s t-test. Results: our study revealed that genotype TT had plasma aldosterone concentration (PAC), ARR and SIT significantly higher in comparison with CC patients. The mean PAC in CC was 12.71 ng/dL vs. 20.55 ng/dL in TT patients (p = 0.037), which consequently gave a higher ARR in TT patients (119 vs. 44, p = 0.034). Mean aldosterone concentration in SIT was 2.40 ng/dL in CC patients and 9.99 ng/dL in TT patients (p = 0.046). Patients with CC genotype required less hypotensive drugs in comparison with TT genotype (p = 0.044). PA was recognized in 16 patients. Nine patients had TC genotype, six TT, and one with CC genotype. Conclusion: our study revealed predisposing TT genotype to PA. Additionally, patients with TT genotype, regardless of the PA presence, had more severe hypertension. The determination of the CYP11B2 promoter polymorphism seems to be useful in the diagnosis of PA, especially in cases where it is difficult to properly prepare patients for hormonal tests or even results of the hormonal test are incoherent.

Purpose: It is possible to raise the rate of the uptake of ¹³¹I in the thyroid gland (RAIU) by increasing the endogenous TSH level through appropriate use of methimazole (MMI) prior to ¹³¹I therapy. The purpose of this paper is to assess the impact of pre treatment with MMI on the efficacy of ¹³¹I therapy in non-toxic multinodular goitre (NMG). Methods: Thirty-one patients with NMG received ¹³¹I treatment in order to reduce the volume of the thyroid (TVR). Those in group 1 (n = 16) were administered 10 mg of methimazole for 6 weeks. Four days after its discontinuation, they received ¹³¹I. Patients in group 2 (n = 15) were given a placebo instead of MMI. The therapeutic activity of ¹³¹I was constant (800 MBq) and was repeated every 6 months. Treatment was discontinued when TVR reached 131I. The median of time until TVR decreased below 40 ml was 9 months [6–12 months] and 18 months [14–22 months] in group 2. At 2 years after the ¹³¹I therapy, the occurrence of hypothyroidism did not differ significantly (36% in group 1 and 33% in group2, p = 0.074). Conclusions: Radioiodine treatment of NMG preceded with appropriate application of MMI is efficient thanks to increased RAIU, shorter period of treatment, and lower frequency of ¹³¹I administration, without an increase in the incidence of post-treatment hypothyroidism.

The most frequently used methods of assessing Graves’ orbithopathy (GO) include: Clinical Activity Score (CAS), ultrasonography (USG), computed tomography (CT), and magnetic resonance imaging (MRI). There exists another, slightly forgotten, imaging method: single-photon emission computed tomography (SPECT) with the use of diethylenetriaminepentaacetic acid tagged with 99mTc (99mTc-DTPA). These days it is possible to conduct a SPECT examination fused with a CT scan (SPECT/CT), which increases the diagnostic value of the investigation. The aim of this paper is to evaluate the usefulness of 99mTc-DTPA SPECT/CT in diagnosing Graves orbitopathy, as compared with other methods. Twenty-three patients with suspected active (infiltrative-edematous) Graves’ orbithopathy were included in the study. Each patient underwent a CAS, an MRI, and a SPECT/CT. The obtained results were analysed statistically, with the assumed statistical significance of p < 0.05. The SPECT/CT and MRI were found to have the highest sensitivity: 0.93 each. The SPECT/CT had the highest specificity: 0.89. MRI and CAS had lower values: 0.78 and 0.56, respectively. The occurrence of an active form of GO had no impact on the exacerbation of exophthalmos or the thickness of the oculomotor muscles. The 99mTc-DTPA SPECT/CT method provides a very good tool for assessing the active form of GO and can, alongside the MRI scan, be used as a referential diagnostic procedure in GO.

Introduction: The aim of this study was the comparison of 24h urine free cortisol (UFC), serum cortisol at 11pm (SCM) and late-nightsalivary cortisol (LSC) in patients suspected for hypercortisolism, and an assessment of the usefulness of these measurements in diagnosingovert Cushing’s (OCS) syndrome, pseudo Cushing’s state (PCS) and subclinical Cushing’s syndrome (SCS). Material and methods: The study group consisted of 82 patients, of whom four patients had SCS, three OCS and eight PCS. For measurementsof LSC, the ELISA method was used, and for UFC and SCM determination, chemiluminescent microparticle immunoassay was used. Results: The highest correlation coefficient characterised LSC and SCM (r = 0.72). Area under curve (AUC) for SCM and LSC in receiveroperating characteristic (ROC) for OCS was: 0.86 v. 0.74; for PCS: 0.83 v. 0.70; and for SCS: 0.74 v. 0.79. Conclusions: Our findings suggest that LSC is more useful compared to SCM in diagnosing subclinical Cushing’s syndrome. Moreover,LSC seems to be a valuable diagnostic criterion to distinguish pseudo Cushing’s state. However, to obtain reliable cut-offs for LSC values,a larger group of hypercortisolic patients is needed. Introduction: The aim of this study was the comparison of 24h urine free cortisol (UFC), serum cortisol at 11pm (SCM) and late-nightsalivary cortisol (LSC) in patients suspected for hypercortisolism, and an assessment of the usefulness of these measurements in diagnosingovert Cushing’s (OCS) syndrome, pseudo Cushing’s state (PCS) and subclinical Cushing’s syndrome (SCS). Material and methods: The study group consisted of 82 patients, of whom four patients had SCS, three OCS and eight PCS. For measurementsof LSC, the ELISA method was used, and for UFC and SCM determination, chemiluminescent microparticle immunoassay was used. Results: The highest correlation coefficient characterised LSC and SCM (r = 0.72). Area under curve (AUC) for SCM and LSC in receiveroperating characteristic (ROC) for OCS was: 0.86 v. 0.74; for PCS: 0.83 v. 0.70; and for SCS: 0.74 v. 0.79. Conclusions: Our findings suggest that LSC is more useful compared to SCM in diagnosing subclinical Cushing’s syndrome. Moreover,LSC seems to be a valuable diagnostic criterion to distinguish pseudo Cushing’s state. However, to obtain reliable cut-offs for LSC values,a larger group of hypercortisolic patients is needed.

Pheochromocytoma is a rare tumour, but one of great clinical importance as a risk factor of malignancy, cardiovascular diseases and sudden death. 15 consecutive patients (eight women and seven men) were hospitalised and submitted for adrenalectomy with pheochromocytoma confirmed by histopathologic examination. Adrenalectomies were performed laparoscopically in 14 cases (93.3%): in nine by the retroperitoneal posterior mode and in five by the transperitoneal lateral approach. Molecular-genetic examination of VHL, RET, SDHB, SDHC and SDHD genes revealed inherited predisposition for PHEO in three of 15 patients (20%): RET mutations typical for MEN 2a in two patients and VHL mutation in one patient. Disturbances of the carbohydrate metabolism occurred in nine patients (60%). Ten patients (66%) reported paroxysmal symptoms. In all cases, with the exception of a von Hippel-Lindau patient, density of tumours exceeded 20 HU. In all studied patients, urine concentration of normetanephrines exceeded their normal range and greatly prevailed over metanephrines values, which were increased in six of them (40%). Urine metoxycatecholamines and increased tissue density are sufficient in pheochromocytoma detection. However, taking into account clinical and supplemental biochemical data may be helpful in the diagnostic process. Laparoscopic adrenalectomy is a fully sufficient and safe method of pheochromocytoma excision.

Introduction: Assessment of the renin-angiotensin-aldosterone system has been recently granted a much greater role in the evaluation of patients with arterial hypertension. There is no single test efficient in selection of patients for second-step etiological investigation. Methods: Altogether, 198 consecutive patients − 119 women (60%) and 79 men (40%) – hospitalized in years 2009–2011 at the Clinical Department of Endocrinology Medical University of Bialystok were diagnosed with primary aldosteronism. In each patient, plasma renin activity and plasma aldosterone concentration (basic and after 2 l NaCl infusion) were evaluated. Results: The percentage of patients with plasma aldosterone concentration ≥15 ng/ml was 53 and the percentage of patients with plasma renin activity ≤0.1 ng/ml/h was 20. The percentage of patients screened for primary aldosteronism in which the aldosterone:renin ratio exceeded consecutive cut-offs of 20, 30, 40 and 50 were respectively 57, 45, 34 and 29. Among 15 patients in which plasma aldosterone concentration after infusion of 2 l of saline was ≥6.5 ng/dl (8.6%), 13 (6.6%) were diagnosed with primary aldosteronism. Conclusion: The obligatory use of tests confirming autonomy of aldosterone secretion in patients screened for primary aldosteronism seems cost-effective in limiting the number of patients for further diagnosis.